脑机接口，国内团队取得关键突破！

Core Insights - The research team from Northwestern Polytechnical University has developed a breakthrough in three-dimensional conical carbon-based flexible cortical electrode arrays, addressing key challenges in the industry such as brain tissue damage, signal attenuation, and poor biocompatibility [1] - The successful technology validation in a space environment marks a significant advancement for brain-machine interfaces (BMIs), paving the way for clinical applications and aerospace uses, showcasing China's leading innovation capabilities in the MEMS field [1] Technical Advancements - The new electrode design features a "soft base and soft needle" integration, allowing for high fidelity brain signal acquisition while ensuring zero damage to the brain cortex [2] - Testing has shown that the signal acquisition precision and stability of the new electrodes are optimized by hundreds of times compared to traditional metal electrodes, with excellent magnetic resonance compatibility for use with high-field MRI equipment [2] - The electrode has passed third-party medical device quality certification, meeting medical standards for biocompatibility and long-term implantation stability, facilitating future clinical applications [2] Industry Trends - The brain-machine interface sector is highlighted as a key focus area in future industry policies, with the Ministry of Industry and Information Technology (MIIT) establishing a dedicated track for BMIs and outlining plans for standardization and innovation from 2023 to 2035 [3] - The market size for brain-machine interfaces in China is projected to reach 3.2 billion yuan in 2024, with a year-on-year growth of 18.8%, and is expected to grow to 5.58 billion yuan by 2027, reflecting a growth rate of 20% [3] Investment Landscape - Investment enthusiasm in the brain-machine interface sector is rising, with 24 financing events recorded in the first 11 months of 2025, marking a 30% increase year-on-year [4] - Over the past five years, nearly 100 financing events have occurred in this sector, with total funding exceeding 10 billion yuan, attracting major investment firms such as Sequoia, Hillhouse, and others [4] - The industry is at a critical juncture for clinical value validation and early commercialization, with strong policy support, high capital interest, and urgent clinical demand driving development, despite challenges from international competition and ethical controversies [4]